Laminin 332 expression in breast carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 2, 2012, Pages 159-164

  Kwon, Soon Young ^a,b   Chae, Seoung W ^a,c   Wilczynski, Sharon P ^d   Arain, Ahmad ^a   Carpenter, Philip M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c Korea University   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

basal like phenotype; breast carcinoma; HER2 dual in situ hybridization; immunohistochemistry; laminin 332; triple negative

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KALININ; PROGESTERONE RECEPTOR; PROTEIN P63;

ARTICLE; CONTROLLED STUDY; DUAL SILVER IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

BIOPSY; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CELL ADHESION MOLECULES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; MALE; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84857911208     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182329e8f     Document Type: Article

References (50)

1. Sasaki T, Fassler R, Hohenester E. Laminin: the crux of basement membrane assembly. J Cell Biol. 2004;164:959-963. (Pubitemid 38429121)
2. Martin GR, Timpl R. Laminin and other basement membrane components. Annu Rev Cell Biol. 1987;3:57-85.
3. Marinkovich MP. Tumour microenvironment: laminin 332 in squamous-cell carcinoma. Nat Rev Cancer. 2007;7:370-380. (Pubitemid 46652480)
4. Patarroyo M, Tryggvason K, Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol. 2002;12:197-207. (Pubitemid 34833063)
5. Sonnenberg A, de Melker AA, Martinez de Velasco AM, et al. Formation of hemidesmosomes in cells of a transformed murine mammary tumor cell line and mechanisms involved in adherence of these cells to laminin and kalinin. J Cell Sci. 1993;106(Pt 4): 1083-1102. (Pubitemid 24018396)
6. Goldfinger LE, Hopkinson SB, deHart GW, et al. The a3 laminin subunit, a6b4 and a3b1 integrin coordinately regulate wound healing in cultured epithelial cells and in the skin. J Cell Sci. 1999;112(Pt 16):2615-2629. (Pubitemid 29429785)
7. Kainulainen T, Hakkinen L, Hamidi S, et al. Laminin-5 expression is independent of the injury and the microenvironment during reepithelialization of wounds. J Histochem Cytochem. 1998;46: 353-360. (Pubitemid 28117385)
8. Zhang K, Kramer RH. Laminin 5 deposition promotes keratinocyte motility. Exp Cell Res. 1996;227:309-322. (Pubitemid 26320173)
9. Ryan MC, Christiano AM, Engvall E, et al. The functions of laminins: lessons from in vivo studies. Matrix Biol. 1996;15:369-381. (Pubitemid 27077631)
10. Giannelli G, Fransvea E, Bergamini C, et al. Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocel-lular carcinoma. Clin Cancer Res. 2003;9(10 Pt 1):3684-3691. (Pubitemid 37169236)
11. Salo S, Haakana H, Kontusaari S, et al. Laminin-5 promotes adhesion and migration of epithelial cells: identification of a migration-related element in the gamma2 chain gene (LAMC2) with activity in transgenic mice. Matrix Biol. 1999;18:197-210. (Pubitemid 29229705)
12. Carpenter PM, Dao AV, Arain ZS, et al. Motility induction in breast carcinoma by mammary epithelial laminin 332 (laminin 5). Mol Cancer Res. 2009;7:462-475.
13. Tsuji T, Kawada Y, Kai-Murozono M, et al. Regulation of melanoma cell migration and invasion by laminin-5 and a3b1 integrin (VLA-3). Clin Exp Metastasis. 2002;19:127-134. (Pubitemid 34264082)
14. Fukushima Y, Ohnishi T, Arita N, et al. a3b1-mediated interaction with laminin-5 stimulates adhesion, migration and invasion of malignant glioma cells. Int J Cancer. 1998;76:63-72. (Pubitemid 28164570)
15. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev Cancer. 2003;3:921-930. (Pubitemid 37500177)
16. Mareel MM, De Baetselier P, Van Roy FM. Mechanisms of Invasion and Metastasis. Boca Raton, FL: CRC Press; 1991:73-220.
17. Kantor JD, Zetter BR. Cell motility in breast cancer. In: Dickson R, Lippman M, eds. Mammary Tumor Cell Cycle, Differentiation and Metastasis. Boston, MA: Kluwer Academic Publishers; 1996:303-323.
18. Stracke ML, Aznavoorian SA, Beckner ME, et al. Cell motility, a principal requirement for metastasis. Exs. 1991;59:147-162.
19. Miyazaki K. Laminin-5 (laminin-332): Unique biological activity and role in tumor growth and invasion. Cancer Sci. 2006;97:91-98. (Pubitemid 43379475)
20. Aumailley M, Bruckner-Tuderman L, Carter WG, et al. A simplified laminin nomenclature. Matrix Biol. 2005;24:326-332. (Pubitemid 41021635)
21. Giannelli G, Antonaci S. Biological and clinical relevance of Laminin-5 in cancer. Clin Exp Metastasis. 2000;18:439-443. (Pubitemid 32844245)
22. Katayama M, Sekiguchi K. Laminin-5 in epithelial tumour invasion. J Mol Histol. 2004;35:277-286. (Pubitemid 40585313)
23. Guess CM, Quaranta V. Defining the role of laminin-332 in carcinoma. Matrix Biol. 2009;28:445-455.
24. Carpenter PM, Wang-Rodriguez J, Chan OT, et al. Laminin 5 expression in metaplastic breast carcinomas. Am J Surg Pathol. 2008;32:345-353. (Pubitemid 351398925)
25. Pyke C, Salo S, Ralfkiaer E, et al. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res. 1995;55:4132-4139.
26. Martin KJ, Kwan CP, Nagasaki K, et al. Down-regulation of laminin-5 in breast carcinoma cells. Mol Med. 1998;4:602-613. (Pubitemid 28523113)
27. Holler E. Laminin isoform expression in breast tumors. Breast Cancer Res. 2005;7:166-167. (Pubitemid 40872781)
28. Henning K, Berndt A, Katenkamp D, et al. Loss of laminin-5 in the epithelium-stroma interface: an immunohistochemical marker of malignancy in epithelial lesions of the breast. Histopathology. 1999;34:305-309. (Pubitemid 29229984)
29. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874. (Pubitemid 32878711)
30. Van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991-1996. (Pubitemid 35434844)
31. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374. (Pubitemid 39100473)
32. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203:661-671. (Pubitemid 38714103)
33. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502. (Pubitemid 43854964)
34. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376. (Pubitemid 351413917)
35. Liu H, Fan Q, Zhang Z, et al. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol. 2008;39:167-174.
36. Fulford LG, Reis-Filho JS, Ryder K, et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res. 2007;9:R41.
37. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res. 2007;9:R16.
38. Tang P, Skinner KA, Hicks DG. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready? Diagn Mol Pathol. 2009;18:125-132.
39. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al. Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol. 2008;3:41.
40. Carbone A, Botti G, Gloghini A, et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn. 2008;10:527-536.
41. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 2002;41(3A):154-161.
42. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443:122-132. (Pubitemid 37056135)
43. Korah R, Das K, Lindy ME, et al. Coordinate loss of fibroblast growth factor 2 and laminin 5 expression during neoplastic progression of mammary duct epithelium. Hum Pathol. 2007;38: 154-160. (Pubitemid 44880211)
44. Miller KA, Eklund EA, Peddinghaus ML, et al. Kruppel-like factor 4 regulates laminin alpha 3A expression in mammary epithelial cells. J Biol Chem. 2001;276:42863-42868.
45. Rae JM, Creighton CJ, Meck JM, et al. MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat. 2007;104:13-19. (Pubitemid 46976633)
46. Diaz LK, Cristofanilli M, Zhou X, et al. b4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol. 2005;18:1165-1175. (Pubitemid 43079915)
47. Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, et al. Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer. 2006;7:396-400. (Pubitemid 46157560)
48. Rodriguez-Pinilla SM, Sarrio D, Honrado E, et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol. 2007;60:1006-1012. (Pubitemid 47441933)
49. Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer. 2008;123:236-240. (Pubitemid 351705215)
50. Lu S, Simin K, Khan A, et al. Analysis of integrin b4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res. 2008;14:1050-1058. (Pubitemid 351302550)